STEP-TEENS

The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.

Definition

Semaglutide 2.4 mg in adolescents aged 12–17 with obesity (Weghuber et al., NEJM 2022). Mean weight reduction 16.7% against 0.6% on placebo. ⚠ Pediatric trials do not measure facial appearance, so anyone citing this trial alongside “Ozempic face” claims is welding two unrelated things together.

STEP-TEENS adolescent semaglutide →

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under Major trials

STEP-1
SURMOUNT-1
SELECT
FLOW
SURMOUNT-OSA
MACE (Major Adverse Cardiovascular Events)
KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire — Clinical Summary Score)
ATTAIN-1
IWQOL-Lite-CT
STEP-4 (withdrawal trial)
SYNERGY-NASH
LEADER (trial)
FLOW (trial)

Where the evidence lives

STEP-TEENS adolescent semaglutide
The full GLP-1 glossary (149 terms, 8 categories)
Research articles — written from primary sources
Tools and calculators
Compare GLP-1 telehealth providers